Combination chemotherapy in advanced carcinoma of the cervix.
Two combinations of Adriamycin, cyclophosphamide, and vincristine, one with and one without 5-fluorouracil, were used to treat 27 patients with advanced cervical cancer. One complete remission (3.7%) and one partial remission (3.7%) were observed; both patients are leading a normal life with no evidence of disease after more than 28 months. Thirteen patients (48.1%) had stable disease for a median duration of 3.0 months but only two showed an improvement in the performance status. No significant difference in the survival rate was noted between those with stable disease and those with progressive disease as analyzed by the life table technique. Despite moderate toxicity, the regimens cannot be recommended for recurrent and advanced carcinoma of the uterine cervix because of the low response rate.
D000505:Alopecia / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002277:Carcinoma / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D009325:Nausea / Q000139:chemically induced; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000401:mortality; D014750:Vincristine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil